Voglibose, the alpha-glucosidase inhibitor Takeda first licensed in Japan as Basen, is taken before each main meal to blunt post-meal glucose spikes in type 2 diabetes, and outside Japan the molecule is supplied almost entirely as generic voglibose tablets.
Voglibose, originated by Takeda Pharmaceutical Company and marketed in Japan since 1994 as Basen, is an oral alpha-glucosidase inhibitor taken with the first bite of each main meal to slow carbohydrate absorption and blunt post-prandial glucose spikes. M Care Exports is a merchant exporter: we source generic voglibose tablets through licensed Indian manufacturing and distribution channels and dispatch on quote, not from our own production line.
Voglibose exporter and bulk supplier from India.
Basen itself has never carried an FDA, EMA or MHRA marketing authorisation; it remains a Japan-registered product, and demand across the rest of Asia, the GCC and Africa is met almost entirely by generic voglibose tablets manufactured to the standard 0.2mg and 0.3mg strengths. M Care quotes generic voglibose against buyer specification, strength mix and destination-market registration status, drawn from licensed WHO-GMP manufacturer lines on the M Care roster, and confirms local registration and any diet-and-exercise formulary conditions attached to a tender line before we release a quote.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Alpha-glucosidase inhibitor (AGI); non-insulinotropic oral antidiabetic, sourced and documented for export.
Voglibose is an alpha-glucosidase inhibitor (AGI), a class that works inside the gut rather than on insulin secretion: it reversibly blocks intestinal alpha-glucosidase enzymes, which delays the breakdown of complex dietary carbohydrates into absorbable glucose and flattens the after-meal glucose surge. Unlike a sulfonylurea or a meglitinide, it does not itself trigger insulin release and carries no monotherapy hypoglycaemia risk. Takeda's flagship licensed use in Japan is improvement of post-prandial hyperglycaemia in type 2 diabetes, alone or added to diet and exercise, and it is also used there as an add-on to other oral agents or insulin; destination-country labelling should always be checked against the specific tender or formulary requirement, since voglibose carries no FDA, EMA or MHRA-approved indication text to fall back on. It is dosed orally with no reconstitution step. Voglibose is supplied as conventional 0.2mg and 0.3mg film-coated tablets and, in Japan, as an orally disintegrating (OD) tablet presentation designed for patients who struggle to swallow standard tablets, such as some elderly formulary populations.
Active ingredient
voglibose. Alpha-glucosidase inhibitor (AGI); non-insulinotropic oral antidiabetic.
Forms and strengths
0.2 mg tablet; 0.3 mg tablet.
Indications
Alpha-glucosidase inhibitor originated by Takeda as Basen, used to reduce post-prandial hyperglycaemia in type 2 diabetes by slowing intestinal carbohydrate breakdown. Never FDA, EMA or MHRA authorised; supplied outside Japan as generic voglibose from Indian WHO-GMP facilities.
Administration
oral. Film-coated tablet, taken with the first bite of each main meal; also supplied in Japan as an orally disintegrating tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for voglibose are hospital and community diabetes pharmacies in markets where alpha-glucosidase inhibitors sit on the oral antidiabetic formulary tier, national and regional MoH tender desks running type 2 diabetes and NCD (non-communicable disease) procurement lists, licensed pharmaceutical wholesalers and importers stocking a diabetes-care range, and NGO or foundation diabetes-prevention programmes evaluating post-prandial glucose control in populations with impaired glucose tolerance. Because voglibose sits outside the FDA, EMA and MHRA regulatory perimeter, buyers are typically markets where an AGI-class product is already a recognised generic formulary line rather than a novel registration.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on voglibose.
Voglibose is dosed at 0.2mg three times daily, taken with the first bite of each main meal rather than before or after it, since a missed or delayed dose relative to eating removes the drug's only mechanism of action. If glycaemic response is inadequate, the dose can be titrated to 0.3mg three times daily; there is no once-daily or fixed mg/kg schedule to reconcile. Voglibose does not cause hypoglycaemia alone, but combining it with a sulfonylurea, meglitinide or insulin raises that risk, so medicines reconciliation should flag any co-prescribed insulin secretagogue. Counsel patients that flatulence, abdominal bloating and softer stools are common early on and usually settle with continued use rather than requiring discontinuation. Voglibose is contraindicated in inflammatory bowel disease, colonic ulceration and intestinal obstruction, since increased intestinal gas can worsen those conditions, and liver enzymes should be checked periodically, since hepatic dysfunction has been reported. No cold-chain handling or admixture is required; storage is controlled room temperature.
The documentation pack a regulator actually asks for.
As an oral solid dosage form, voglibose travels on standard ambient-temperature logistics rather than the validated cold-chain lanes M Care runs for biologics. The documentation buyers need is the conventional generic-tablet file: batch-specific certificate of analysis, CDSCO export paperwork from the Indian side, and CTD or eCTD-aligned dossier support where the destination regulator requires local registration before import or tender-listing. Voglibose is not on the WHO Model List of Essential Medicines, which for oral type 2 diabetes therapy lists metformin, sulfonylureas and, since the 2025 update, GLP-1 receptor agonists; a 2018 Cochrane review of alpha-glucosidase inhibitors for diabetes prevention (which pooled two voglibose trials among ten included studies) found voglibose reduced progression to type 2 diabetes in people with impaired glucose tolerance, evidence that supports its formulary-specific role in diabetes-prevention and post-prandial-control tenders rather than a first-line EML position. On brand versus generic, there is no live choice for a buyer outside Japan: Basen has never held FDA, EMA or MHRA marketing authorisation, so every voglibose tender M Care quotes outside Japan is generic voglibose manufactured to WHO-GMP standard by an Indian partner site, not a branded originator product. We do not manufacture voglibose ourselves and hold no WHO-GMP or WHO-PQ certification in our own name; every batch we export carries its manufacturing partner's own certification.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside voglibose.
Dapagliflozin
Another diabetes & endocrine line ordered on the same formularies.
Dapagliflozin metformin
Another diabetes & endocrine line ordered on the same formularies.
Dulaglutide
Another diabetes & endocrine line ordered on the same formularies.
All diabetes & endocrine
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for voglibose.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Voglibose supply, the specific questions.
Is voglibose approved by the FDA, EMA or MHRA?
No. Voglibose has only ever held marketing authorisation in Japan, where Takeda has sold it as Basen since 1994. It has never been approved by the FDA, EMA or MHRA, so it does not appear on those regulators' formularies. Buyers in our served markets source it as a locally registered generic rather than a US, EU or UK-licensed brand.
What is voglibose licensed to treat?
Its flagship use, per Takeda's Japanese licensing, is improving post-prandial hyperglycaemia in type 2 diabetes, taken alone or with diet and exercise, and it is also used as an add-on to other oral antidiabetic agents or insulin. It works by slowing carbohydrate breakdown in the gut rather than stimulating insulin release. Destination-country labelling should be checked against the exact tender or formulary specification.
How is voglibose dosed?
The standard dose is 0.2mg taken orally three times daily with the first bite of each main meal, titrated to 0.3mg three times daily if the glycaemic response is inadequate. Timing relative to the meal matters more than for most oral antidiabetics, since a dose taken after eating has largely missed its window of action.
Does voglibose cause hypoglycaemia on its own?
No. Voglibose slows carbohydrate absorption rather than stimulating insulin secretion, so it carries no monotherapy hypoglycaemia risk. Combining it with a sulfonylurea, a meglitinide or insulin does raise that risk, so any co-prescribed insulin secretagogue should be flagged at dispensing.
What side effects and contraindications should a pharmacy counsel on?
Flatulence, abdominal bloating and softer stools are common early in treatment and usually settle with continued use. Voglibose is contraindicated in inflammatory bowel disease, colonic ulceration and intestinal obstruction, since it can increase intestinal gas, and periodic liver-function monitoring is advised given reports of hepatic enzyme elevation.
Does voglibose need cold-chain shipping?
No. It is a conventional or orally disintegrating film-coated tablet stored at controlled room temperature, so it moves on standard ambient logistics rather than the validated cold-chain lanes M Care uses for biologics and insulins.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-13.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.